- Home
- GH vs BFAM Comparison
GH vs BFAM Comparison
Compare GH & BFAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- BFAM
- Stock Information
- Founded
- GH 2011
- BFAM 1986
- Country
- GH United States
- BFAM United States
- Employees
- GH N/A
- BFAM N/A
- Industry
- GH Medical Specialities
- BFAM Other Consumer Services
- Sector
- GH Health Care
- BFAM Consumer Discretionary
- Exchange
- GH Nasdaq
- BFAM Nasdaq
- Market Cap
- GH 4.9B
- BFAM 5.7B
- IPO Year
- GH 2018
- BFAM 1997
- Fundamental
- Price
- GH $98.28
- BFAM $99.03
- Analyst Decision
- GH Strong Buy
- BFAM Buy
- Analyst Count
- GH 22
- BFAM 7
- Target Price
- GH $74.32
- BFAM $132.43
- AVG Volume (30 Days)
- GH 3.4M
- BFAM 946.8K
- Earning Date
- GH 10-29-2025
- BFAM 10-30-2025
- Dividend Yield
- GH N/A
- BFAM N/A
- EPS Growth
- GH N/A
- BFAM 72.80
- EPS
- GH N/A
- BFAM 3.47
- Revenue
- GH $902,569,000.00
- BFAM $2,874,055,000.00
- Revenue This Year
- GH $33.95
- BFAM $11.17
- Revenue Next Year
- GH $25.77
- BFAM $6.93
- P/E Ratio
- GH N/A
- BFAM $28.71
- Revenue Growth
- GH 30.38
- BFAM 9.38
- 52 Week Low
- GH $28.45
- BFAM $91.49
- 52 Week High
- GH $101.57
- BFAM $132.99
- Technical
- Relative Strength Index (RSI)
- GH 77.88
- BFAM 46.01
- Support Level
- GH $88.88
- BFAM $95.87
- Resistance Level
- GH $97.51
- BFAM $99.99
- Average True Range (ATR)
- GH 4.94
- BFAM 3.46
- MACD
- GH 1.89
- BFAM 0.36
- Stochastic Oscillator
- GH 88.05
- BFAM 42.32
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About BFAM Bright Horizons Family Solutions Inc.
Bright Horizons Family Solutions Inc provider of early education and child care, family care solutions, and workforce education services that help working families and client employees personally and professionally. It provides services under multi-year contracts with employers that offer early education and child care, back-up care, and educational advisory services as part of their employee benefits package. The company has three business segments; full-service center-based child care, backup care, and educational advisory services. The majority of the revenue is generated by full-service center-based child care, which includes traditional center-based child care and early education services. Other services provided by the company include in-home child and elder care, and Others.